The Quest to ‘Solve All Diseases’ with AI: Isomorphic Labs’ Max Jaderberg

Isomorphic Labs is transforming drug discovery by building a general-purpose AI engine capable of navigating the vast chemical space of 10^60 potential molecules. Chief AI Officer Max Jaderberg explains that moving beyond traditional supervised learning, the company utilizes reinforcement learning and diffusion-based architectures to model complex biomolecular interactions. AlphaFold 3 serves as a foundational tool, providing experimental-level accuracy for protein, DNA, and ligand interactions without requiring task-specific fine-tuning. Beyond predictive modeling, the goal is to develop autonomous agents that explore molecular space with superhuman creativity, akin to AlphaGo’s "Move 37." This approach aims to solve diseases by uncovering therapeutic designs that exceed human intuition, ultimately establishing AI as an essential, foundational tool for the future of the pharmaceutical industry.